

# Gujarat Gas

Refer to important disclosures at the end of this report

## Volumes slide, while margins rise; outlook volatile; downgrade to HOLD

- Gujarat Gas (GGL) reported Q2FY23 EBITDA/PAT of Rs6.43bn/4.04bn (up 53%/65% YoY and 6% each QoQ), at 33%/40% above our estimates on gross margin beat, as lower-than-expected volumes led to decline in spot LNG intake and, hence, reduced gas cost.
- Total gas sales volume fell 33% YoY and 22% QoQ to 7.6mmscmd (a 3% miss). Industrial PNG was down 49% YoY/33% QoQ to 4.5mmscmd, owing to Morbi. CNG rose 18% YoY but was down 5% QoQ, at 2.3mmscmd. Domestic PNG was up 8% YoY, at 0.7mmscmd.
- Net realization fell 3% QoQ, while unit gas cost declined 10%, resulting in 32% expansion in gross margin to Rs13/scm (at a 27% beat). Unit opex jumped to Rs3.8/scm. EBITDA/scm was up 34% QoQ to Rs9.2 (up, over 2x YoY).
- We tweak our EPS estimates, assuming lower volumes albeit higher margins now, and cut our TP by 4% to Rs520. Owing to the recent stock run-up and the volatile winter, with competition from propane and potential price cuts, we downgrade GGL to HOLD from Buy.

**Highlights:** Commercial PNG volumes were up 17% YoY/8% QoQ in Q2FY23, at 0.14mmscmd. Morbi volumes fell, from 4.7mmscmd to 2.7mmscmd QoQ (due to shutdown in tiles and ceramic units), while non Morbi industrial was also slightly down, from 1.9mmscmd to 1.8mmscmd QoQ. Employee cost rose 13% YoY/7% QoQ, while Other Expenditure was up 23% YoY/down 2% QoQ, at Rs2.15bn. Interest cost fell 4% QoQ to Rs131mn. GGL's current volumes, as per our checks, are <8mmscmd, with Morbi at 2.8-3.0mmscmd. GGL added 20 CNG stations, and 45,400 DPNG & 257 commercial customers in Q2. GGL also commissioned 61 new IPNG customers. Signed but yet to be commissioned volumes stood at 0.56mmscmd. H1FY23 capex stands at Rs4.9bn.

**Guidance:** Competition from propane has hit demand for PNG; propane is Rs12-13/scm cheaper than IPNG now. Propane price is up, on oversupply from China (slowdown), though the pricing anomaly should be resolved as China normalizes. GGL has taken a price cut in IPNG recently, in USD terms, to account for Rupee depreciation. It is open to more price cuts, for attracting demand. At a Rs4-5/scm price difference between propane and IPNG, there should not be any fuel shift. GGL used spot LNG in July (in Q2), but after the August volume reduction, no spot was used. It is, in fact, using some term LNG in the CNG segment. USD25/mmbtu spot is tied to ~9mmscmd of total volume. Mgmt maintains longer-term volume & margin guidance. CNG volumes should grow at 15-20% YoY. GGL expects a positive outcome for the CGD sector from the Kirit Parikh report. FY23 capex guidance is Rs10-11bn.

**Valuation:** We value GGL on DCF methodology, with revised Sep-23 TP of Rs520. Key risks: Adverse oil-gas-LNG prices; currency, regulations, competition, operational-project issues.

Please see our sector model portfolio (Emkay Alpha Portfolio): [Oil & Gas \(Page 7\)](#)

### Financial Snapshot (Standalone)

(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	98,664	1,64,562	1,76,623	1,97,502	2,24,908
EBITDA	20,842	20,763	22,057	24,687	27,934
EBITDA Margin (%)	21.1	12.6	12.5	12.5	12.4
APAT	12,682	12,946	13,640	15,624	18,010
EPS (Rs)	18.4	18.8	19.8	22.7	26.2
EPS (% chg)	40.4	2.1	5.4	14.5	15.3
ROE (%)	32.8	25.8	22.0	20.9	20.2
P/E (x)	26.9	26.3	25.0	21.8	18.9
EV/EBITDA (x)	16.7	16.8	15.6	13.7	11.8
P/BV (x)	7.7	6.1	5.0	4.2	3.5

Source: Company, Emkay Research

<b>CMP</b> Rs 495 as of (November 10, 2022)	<b>Target Price</b> Rs 520 (▼) 12 months
<b>Rating</b> HOLD (▼)	<b>Upside</b> 5.0 %

### Change in Estimates

EPS Chg FY23E/FY24E (%)	2/(5)
Target Price change (%)	(3.6)
Target Period (Months)	12
Previous Reco	BUY

### Emkay vs Consensus

EPS Estimates		
	FY23E	FY24E
Emkay	19.8	22.7
Consensus	19.6	22.9
Mean Consensus TP (12M)	Rs 530	

### Stock Details

Bloomberg Code	GUJGA IN
Face Value (Rs)	2
Shares outstanding (mn)	688
52 Week H/L	722 / 404
M Cap (Rs bn/USD bn)	341 / 4.17
Daily Avg Volume (nos.)	14,41,894
Daily Avg Turnover (USD mn)	8.7


### Shareholding Pattern Sep '22

Promoters	60.9%
FIIIs	5.0%
DIIIs	13.0%
Public and Others	21.1%

### Price Performance

(%)	1M	3M	6M	12M
<b>Absolute</b>	1	9	(2)	(25)
<b>Rel. to Nifty</b>	(4)	6	(12)	(25)

### Relative price trend



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

#### Sabri Hazarika

sabri.hazarika@emkayglobal.com  
+91 22 6612 1282

#### Harsh Maru

harsh.maru@emkayglobal.com  
+91 22 6612 1336

## Exhibit 1: Actuals vs. Estimates (Q2FY23)

Rs mn	Actual	Estimates (Emkay)	Consensus Estimates (Bloomberg)	Variation		Comments
				Emkay	Consensus	
Total Revenue	39,765	43,277	39,307	-8%	1%	Lower volumes
Adjusted EBITDA	6,427	4,841	5,642	33%	14%	Lower input gas costs
EBITDA Margin	16.2%	11.2%	14.4%	500bps	180bps	
Adjusted Net Profit	4,039	2,884	3,554	40%	14%	

Source: Company, Emkay Research

## Exhibit 2: Quarterly Summary

Rs mn	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	YoY	QoQ	H1FY22	H1FY23	YoY
<b>Net Sales</b>	<b>36,249</b>	<b>51,444</b>	<b>46,694</b>	<b>51,701</b>	<b>39,765</b>	<b>10%</b>	<b>-23%</b>	<b>66,424</b>	<b>91,465</b>	<b>38%</b>
Dec./(Inc.) in Stock In Trade	-20	-50	3	-42	30			-25	-12	
Raw Material Cost	29,887	46,714	37,197	43,015	30,654	3%	-29%	50,531	73,669	46%
Purchases	-	-	-	-	-			-	-	
<b>Total COGS</b>	<b>29,867</b>	<b>46,664</b>	<b>37,199</b>	<b>42,973</b>	<b>30,684</b>	<b>3%</b>	<b>-29%</b>	<b>50,506</b>	<b>73,657</b>	<b>46%</b>
<b>Adjusted Gross Profit</b>	<b>6,382</b>	<b>4,780</b>	<b>9,495</b>	<b>8,728</b>	<b>9,081</b>	<b>42%</b>	<b>4%</b>	<b>15,919</b>	<b>17,808</b>	<b>12%</b>
Employee Cost	445	469	490	472	503	13%	7%	950	975	3%
Other Expenses	1,747	1,937	2,031	2,190	2,150	23%	-2%	3,554	4,340	22%
<b>OPEX</b>	<b>2,192</b>	<b>2,405</b>	<b>2,520</b>	<b>2,662</b>	<b>2,653</b>	<b>21%</b>	<b>0%</b>	<b>4,505</b>	<b>5,315</b>	<b>18%</b>
<b>Adjusted EBITDA</b>	<b>4,190</b>	<b>2,375</b>	<b>6,974</b>	<b>6,066</b>	<b>6,427</b>	<b>53%</b>	<b>6%</b>	<b>11,414</b>	<b>12,494</b>	<b>9%</b>
Depreciation	947	969	1,021	1,032	1,064	12%	3%	1,860	2,096	13%
<b>EBIT</b>	<b>3,243</b>	<b>1,406</b>	<b>5,954</b>	<b>5,035</b>	<b>5,363</b>	<b>65%</b>	<b>7%</b>	<b>9,554</b>	<b>10,398</b>	<b>9%</b>
Interest Cost	124	140	145	136	131	6%	-4%	284	267	-6%
Other Income	178	353	176	190	185	4%	-2%	378	375	-1%
PBT Before Exceptional Items	3,297	1,619	5,986	5,089	5,418	64%	6%	9,649	10,506	9%
Exceptional Items	-	-	-119	-	-			-	-	
<b>PBT</b>	<b>3,297</b>	<b>1,619</b>	<b>5,867</b>	<b>5,089</b>	<b>5,418</b>	<b>64%</b>	<b>6%</b>	<b>9,649</b>	<b>10,506</b>	<b>9%</b>
Current Tax	766	438	1,432	1,221	1,307	71%	7%	2,290	2,528	10%
Deferred Tax	77	-38	-9	57	72	-7%	27%	164	128	-22%
Total Tax	843	400	1,424	1,278	1,379	64%	8%	2,455	2,656	8%
<b>Reported PAT</b>	<b>2,454</b>	<b>1,219</b>	<b>4,443</b>	<b>3,811</b>	<b>4,039</b>	<b>65%</b>	<b>6%</b>	<b>7,194</b>	<b>7,850</b>	<b>9%</b>
Reported EPS (Rs.)	3.6	1.8	6.5	5.5	5.9	65%	6%	10.5	11.4	9%
Adjusted PAT	2,454	1,219	4,533	3,811	4,039	65%	6%	7,194	7,850	9%
Adjusted EPS (Rs.)	3.6	1.8	6.6	5.5	5.9	65%	6%	10.5	11.4	9%
Shares O/S (mn)	688	688	688	688	688	0%	0%	688	688	0%
EBITDA Margin	12%	5%	15%	12%	16%			17%	14%	
NPM	7%	2%	10%	7%	10%			11%	9%	
Effective Tax Rate	26%	25%	24%	25%	25%			25%	25%	
<b>Sales Volume (mmscmd)</b>	<b>11.4</b>	<b>11.4</b>	<b>9.9</b>	<b>9.8</b>	<b>7.6</b>	<b>-33%</b>	<b>-22%</b>	<b>10.7</b>	<b>8.7</b>	<b>-19%</b>
Industrial PNG	8.7	8.4	6.7	6.6	4.5	-49%	-33%	8.2	5.5	-33%
Commercial PNG	0.1	0.1	0.1	0.1	0.1	17%	8%	0.1	0.1	30%
Domestic PNG	0.6	0.7	0.8	0.6	0.7	8%	25%	0.6	0.6	1%
CNG	2.0	2.2	2.2	2.4	2.3	18%	-5%	1.8	2.4	36%
Average Realisation (Rs/scm)	34.5	49.1	52.5	58.3	56.7	64%	-3%	33.9	57.6	70%
<b>Gross Margin (Rs/scm)</b>	<b>6.1</b>	<b>4.6</b>	<b>10.7</b>	<b>9.8</b>	<b>13.0</b>	<b>113%</b>	<b>32%</b>	<b>8.1</b>	<b>11.2</b>	<b>38%</b>
Opex (Rs/scm)	2.1	2.3	2.8	3.0	3.8	81%	26%	2.3	3.3	46%
<b>EBITDA/scm (Rs)</b>	<b>4.0</b>	<b>2.3</b>	<b>7.8</b>	<b>6.8</b>	<b>9.2</b>	<b>130%</b>	<b>34%</b>	<b>5.8</b>	<b>7.9</b>	<b>35%</b>

Source: Company, Emkay Research

Note: Some numbers may not fully match with annual tables due to different adjustment method in the Emkay detailed annual model, averaging discrepancies, and past revisions

**Exhibit 3: Change in assumptions**

	FY23E			FY24E			FY25E		
	Previous	Revised	Variance	Previous	Revised	Variance	Previous	Revised	Variance
EBITDA/scm (Rs)	6.0	6.9	16%	6.1	6.5	7%	6.1	6.6	8%
Volumes (mmscmd)	10.0	8.8	-13%	11.6	10.3	-11%	12.7	11.6	-9%
Growth	-6%	-18%	-1,200bps	15%	18%	269bps	10%	12%	230bps

Source: Company, Emkay Research

**Exhibit 4: Change in estimates**

(Rs mn)	FY23E			FY24E			FY25E		
	Previous	Revised	Variance	Previous	Revised	Variance	Previous	Revised	Variance
Revenue	2,05,708	1,76,623	-14%	2,32,924	1,97,502	-15%	2,60,580	2,24,908	-14%
EBITDA	21,878	22,057	1%	25,832	24,687	-4%	28,503	27,934	-2%
EBITDA Margins	10.6%	12.5%	185bps	11.1%	12.5%	141bps	10.9%	12.4%	148bps
PAT	13,416	13,640	2%	16,423	15,624	-5%	18,369	18,010	-2%
EPS (Rs)	19.5	19.8	2%	23.9	22.7	-5%	26.7	26.2	-2%

Source: Company, Emkay Research

**Exhibit 5: DCF-based valuation (Sep-23 TP)**

Assumptions	Sep-24E (Rs mn)		
Risk Free Rate	7.0%	NPV Of FCF	1,61,464
Risk Premium	5.3%	Terminal Value	6,58,937
Beta	0.7	PV Of TV	1,93,653
Cost Of Equity	10.8%	Total Value	3,55,118
Cost Of Debt	10.0%	Less: Adjusted Net Debt (Y/E)	-2,990
Post Tax Cost Of Debt	7.5%	<b>Equity Value</b>	<b>3,58,108</b>
Average Debt-to-Equity	0.6%	No. Of Shares O/S (mn)	688
<b>WACC</b>	<b>10.7%</b>	<b>Target Price (Rs)</b>	<b>520</b>
Terminal Growth Rate	3.0%		

Source: Company, Emkay Research

**Exhibit 6: P/E-based valuation (on Sep-24E EPS)**

Rs	FY20	FY21	FY22	FY23E	FY24E	FY25E
Adjusted EPS	13.1	18.4	18.8	19.8	22.7	26.2
<b>Target Multiple (x)</b>						<b>21.3</b>
<b>DCF Target Price</b>						<b>520</b>

Source: Company, Emkay Research

**Key Financials (Standalone)****Income Statement**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
<b>Revenue</b>	<b>98,664</b>	<b>1,64,562</b>	<b>1,76,623</b>	<b>1,97,502</b>	<b>2,24,908</b>
<b>Expenditure</b>	<b>77,823</b>	<b>1,43,799</b>	<b>1,54,566</b>	<b>1,72,815</b>	<b>1,96,974</b>
<b>EBITDA</b>	<b>20,842</b>	<b>20,763</b>	<b>22,057</b>	<b>24,687</b>	<b>27,934</b>
Depreciation	3,436	3,849	4,267	4,782	5,277
<b>EBIT</b>	<b>17,406</b>	<b>16,914</b>	<b>17,790</b>	<b>19,905</b>	<b>22,657</b>
Other Income	714	907	941	1,086	1,441
Interest expenses	1,168	568	496	104	20
<b>PBT</b>	<b>16,953</b>	<b>17,253</b>	<b>18,235</b>	<b>20,887</b>	<b>24,078</b>
Tax	4,272	4,278	4,595	5,264	6,068
Extraordinary Items	0	(30)	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
<b>Reported Net Income</b>	<b>12,682</b>	<b>12,856</b>	<b>13,640</b>	<b>15,624</b>	<b>18,010</b>
<b>Adjusted PAT</b>	<b>12,682</b>	<b>12,946</b>	<b>13,640</b>	<b>15,624</b>	<b>18,010</b>

**Balance Sheet**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity share capital	1,377	1,377	1,377	1,377	1,377
Reserves & surplus	43,110	54,616	66,619	80,212	95,701
<b>Net worth</b>	<b>44,486</b>	<b>55,993</b>	<b>67,996</b>	<b>81,589</b>	<b>97,078</b>
<b>Minority Interest</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Loan Funds</b>	<b>11,099</b>	<b>7,190</b>	<b>4,190</b>	<b>3,190</b>	<b>2,890</b>
Net deferred tax liability	7,925	8,077	8,196	8,316	8,436
<b>Total Liabilities</b>	<b>63,511</b>	<b>71,260</b>	<b>80,382</b>	<b>93,094</b>	<b>1,08,404</b>
<b>Net block</b>	<b>63,410</b>	<b>70,668</b>	<b>77,799</b>	<b>84,409</b>	<b>90,519</b>
<b>Investment</b>	<b>211</b>	<b>237</b>	<b>237</b>	<b>237</b>	<b>237</b>
<b>Current Assets</b>	<b>14,151</b>	<b>14,725</b>	<b>17,164</b>	<b>23,946</b>	<b>34,009</b>
Cash & bank balance	3,189	211	1,790	7,179	15,455
Other Current Assets	55	168	173	178	184
<b>Current liabilities &amp; Provision</b>	<b>21,576</b>	<b>24,293</b>	<b>25,039</b>	<b>26,026</b>	<b>27,204</b>
<b>Net current assets</b>	<b>(7,425)</b>	<b>(9,569)</b>	<b>(7,875)</b>	<b>(2,079)</b>	<b>6,805</b>
Misc. exp	0	0	0	0	0
<b>Total Assets</b>	<b>63,511</b>	<b>71,260</b>	<b>80,382</b>	<b>93,094</b>	<b>1,08,404</b>

**Cash Flow**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
<b>PBT (Ex-Other income) (NI+Dep)</b>	<b>16,239</b>	<b>16,346</b>	<b>17,294</b>	<b>19,801</b>	<b>22,637</b>
Other Non-Cash items	350	313	0	0	0
Chg in working cap	1,099	(682)	3	(286)	(487)
<b>Operating Cashflow</b>	<b>16,588</b>	<b>16,618</b>	<b>17,334</b>	<b>19,002</b>	<b>21,240</b>
Capital expenditure	(10,378)	(13,716)	(11,695)	(11,699)	(11,703)
<b>Free Cash Flow</b>	<b>6,210</b>	<b>2,902</b>	<b>5,639</b>	<b>7,303</b>	<b>9,537</b>
Investments	(11)	(26)	0	0	0
Other Investing Cash Flow	3,550	(101)	131	135	139
<b>Investing Cashflow</b>	<b>(6,124)</b>	<b>(12,935)</b>	<b>(10,623)</b>	<b>(10,478)</b>	<b>(10,123)</b>
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(9,455)	(3,909)	(3,000)	(1,000)	(300)
Dividend paid (incl tax)	(863)	(1,375)	(1,637)	(2,031)	(2,521)
Other Financing Cash Flow	(2,707)	(808)	0	0	0
<b>Financing Cashflow</b>	<b>(14,192)</b>	<b>(6,660)</b>	<b>(5,133)</b>	<b>(3,135)</b>	<b>(2,841)</b>
<b>Net chg in cash</b>	<b>(3,728)</b>	<b>(2,978)</b>	<b>1,579</b>	<b>5,390</b>	<b>8,276</b>
Opening cash position	6,917	3,189	211	1,790	7,179
<b>Closing cash position</b>	<b>3,189</b>	<b>211</b>	<b>1,790</b>	<b>7,179</b>	<b>15,455</b>

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/14/2022 01:49 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY&lt;GO&gt;. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

**Key Ratios**

<b>Profitability (%)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
EBITDA Margin	21.1	12.6	12.5	12.5	12.4
EBIT Margin	17.6	10.3	10.1	10.1	10.1
Effective Tax Rate	25.2	24.8	25.2	25.2	25.2
Net Margin	12.9	7.9	7.7	7.9	8.0
ROCE	29.0	26.4	24.7	24.2	23.9
ROE	32.8	25.8	22.0	20.9	20.2
RoIC	25.7	22.4	20.6	20.8	21.6

<b>Per Share Data (Rs)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
EPS	18.4	18.8	19.8	22.7	26.2
CEPS	23.4	24.4	26.0	29.6	33.8
BVPS	64.6	81.3	98.8	118.5	141.0
DPS	2.0	2.0	2.4	3.0	3.7

<b>Valuations (x)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
PER	26.9	26.3	25.0	21.8	18.9
P/CEPS	21.2	20.3	19.0	16.7	14.6
P/BV	7.7	6.1	5.0	4.2	3.5
EV / Sales	3.6	2.1	2.0	1.7	1.5
EV / EBITDA	16.7	16.8	15.6	13.7	11.8
Dividend Yield (%)	0.4	0.4	0.5	0.6	0.7

<b>Gearing Ratio (x)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
Net Debt/ Equity	0.2	0.1	0.0	0.0	(0.1)
Net Debt/EBIDTA	0.4	0.3	0.1	(0.2)	(0.4)
Working Cap Cycle (days)	9.6	10.5	10.5	10.5	10.5

<b>Growth (%)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
Revenue	(4.2)	66.8	7.3	11.8	13.9
EBITDA	27.5	(0.4)	6.2	11.9	13.2
EBIT	32.2	(2.8)	5.2	11.9	13.8
PAT	6.3	1.4	6.1	14.5	15.3

<b>Quarterly (Rs mn)</b>	<b>Q2FY22</b>	<b>Q3FY22</b>	<b>Q4FY22</b>	<b>Q1FY23</b>	<b>Q2FY23</b>
Revenue	36,249	51,444	46,694	51,701	39,765
EBITDA	4,190	2,375	6,974	6,066	6,427
<b>EBITDA Margin (%)</b>	<b>11.6</b>	<b>4.6</b>	<b>14.9</b>	<b>11.7</b>	<b>16.2</b>
PAT	2,454	1,219	4,443	3,811	4,039
<b>EPS (Rs)</b>	<b>3.6</b>	<b>1.8</b>	<b>6.5</b>	<b>5.5</b>	<b>5.9</b>

Source: Company, Emkay Research

<b>Shareholding Pattern (%)</b>	<b>Sep-21</b>	<b>Dec-21</b>	<b>Mar-22</b>	<b>Jun-22</b>	<b>Sep-22</b>
Promoters	60.9	60.9	60.9	60.9	60.9
FIs	7.9	7.7	6.0	5.2	5.0
DIs	8.1	8.0	9.5	10.0	13.0
Public and Others	23.2	23.4	23.6	23.9	21.1


Source: Capitaline

## RECOMMENDATION HISTORY (Rs/share)

Date	Closing Price	TP	Period	Rating	Analyst
04-Aug-22	444	540	12m	Buy	Sabri Hazarika
11-May-22	537	630	12m	Buy	Sabri Hazarika
10-Feb-22	648	670	12m	Hold	Sabri Hazarika
23-Nov-21	648	630	12m	Hold	Sabri Hazarika
29-Oct-21	622	630	12m	Hold	Sabri Hazarika
26-Jul-21	715	520	12m	Hold	Sabri Hazarika
23-Jun-21	653	520	12m	Hold	Sabri Hazarika
02-Jun-21	567	520	12m	Hold	Sabri Hazarika
29-May-21	511	520	12m	Hold	Sabri Hazarika
23-Apr-21	546	520	12m	Hold	Sabri Hazarika
22-Mar-21	510	520	12m	Hold	Sabri Hazarika
04-Mar-21	544	520	12m	Hold	Sabri Hazarika
18-Feb-21	478	475	12m	Buy	Sabri Hazarika
05-Feb-21	380	475	12m	Buy	Sabri Hazarika
27-Nov-20	349	375	12m	Buy	Sabri Hazarika
06-Nov-20	313	375	12m	Buy	Sabri Hazarika
28-Sep-20	302	365	12m	Buy	Sabri Hazarika
05-Aug-20	308	365	12m	Buy	Sabri Hazarika
06-Jun-20	286	260	12m	Hold	Sabri Hazarika
06-May-20	235	280	12m	Hold	Sabri Hazarika
06-Feb-20	302	280	12m	Hold	Sabri Hazarika
24-Jan-20	294	235	12m	Buy	Sabri Hazarika
04-Dec-19	217	235	12m	Buy	Sabri Hazarika

Source: Company, Emkay Research

## RECOMMENDATION HISTORY (Rs/share)



Source: Bloomberg, Company, Emkay Research

## Emkay Alpha Portfolio – Oil & Gas



**Analyst: Sabri Hazarika**

### Contact Details

sabri.hazarika@emkayglobal.com  
+91 22 6612 1282

### Sector

Oil & Gas

### Analyst bio

Sabri Hazarika holds an MBA and comes with 12 years of research experience. His team currently covers 12 stocks in the Indian Oil & Gas space.

### EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight based on Current NAV	Change vs last published EAP (bps)
<b>Oil &amp; Gas</b>	<b>10.07</b>	<b>10.01</b>	<b>-1%</b>	<b>-6</b>	<b>100.00</b>	
BPCL	0.27	0.29	9%	2	2.89	0
GAIL	0.22	0.24	9%	2	2.34	0
Gujarat Gas	0.08	0.07	-13%	-1	0.71	-7
Gujarat State Petronet	0.00	0.01	NA	1	0.10	0
Gulf Oil Lubricants	0.00	0.00	NA	0	0.00	0
HPCL	0.12	0.13	9%	1	1.30	0
Indian Oil	0.24	0.26	9%	2	2.63	-3
Indraprastha Gas	0.14	0.16	15%	2	1.55	0
Petronet LNG	0.15	0.16	8%	1	1.57	0
Oil India	0.06	0.07	16%	1	0.74	0
ONGC	0.50	0.58	16%	8	5.76	0
Reliance Industries	8.30	8.04	-3%	-26	79.84	0
<b>Cash</b>	<b>0.00</b>	<b>0.06</b>	<b>NA</b>	<b>6</b>	<b>0.56</b>	<b>5</b>

Source: Emkay Research

■ High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight

### Sector portfolio NAV

	Base					Latest
	1-Apr-19	10-Nov-21	11-May-22	10-Aug-22	7-Oct-22	9-Nov-22
EAP - Oil & Gas	100.0	160.5	151.8	155.2	147.2	155.9
BSE200 Neutral Weighted Portfolio (ETF)	100.0	159.6	150.7	154.2	146.3	155.2

\*Performance measurement base date 1st April 2019


Source: Emkay Research

### Price Performance (%)

	1m	3m	6m	12m
EAP - Oil & Gas	6.0%	0.5%	2.8%	-2.9%
BSE200 Neutral Weighted Portfolio (ETF)	6.1%	0.6%	3.0%	-2.8%

Source: Emkay Research

### NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): [Nifty](#)

Please see our model portfolio (Emkay Alpha Portfolio): [SMID](#)

“Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals”

## Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 11 Nov 2022 04:10:09 (SGT)

Dissemination Date: 11 Nov 2022 04:11:09 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com)

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/14/2022 01:49 PM



**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of November 11, 2022
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:**
3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of November 11, 2022.
5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 11, 2022
6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment services or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the November 11, 2022

**RESTRICTIONS ON DISTRIBUTION**

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com